BR9912209A - Resources and methods for monitoring nucleoside reverse transcriptase inhibitor antiretroviral therapy and guide therapeutic decisions in the treatment of HIV / AIDS - Google Patents

Resources and methods for monitoring nucleoside reverse transcriptase inhibitor antiretroviral therapy and guide therapeutic decisions in the treatment of HIV / AIDS

Info

Publication number
BR9912209A
BR9912209A BR9912209-0A BR9912209A BR9912209A BR 9912209 A BR9912209 A BR 9912209A BR 9912209 A BR9912209 A BR 9912209A BR 9912209 A BR9912209 A BR 9912209A
Authority
BR
Brazil
Prior art keywords
hiv
aids
resources
methods
reverse transcriptase
Prior art date
Application number
BR9912209-0A
Other languages
Portuguese (pt)
Inventor
Christos J Petropoulos
Jeanette Whitcomb
Original Assignee
Virologic Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Virologic Inc filed Critical Virologic Inc
Publication of BR9912209A publication Critical patent/BR9912209A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/702—Specific hybridization probes for retroviruses
    • C12Q1/703—Viruses associated with AIDS

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • AIDS & HIV (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

"RECURSOS E MéTODOS PARA MONITORAçãO DE TERAPIA ANTI-RETROVIRAL INIBIDORA DE TRANSCRIPTASE REVERSA DE NUCLEOSìDEO E GUIA DE DECISõES TERAPêUTICAS NO TRATAMENTO DE HIV/AIDS". Esta invenção refere-se a testes de suscetibilidade e resistência à droga antiviral a serem empregados em identificação de regimes de droga eficaz para o tratamento de infecção de vírus da imunodeficiência humana (HIV) e síndrome da imunodeficiência adquirida (AIDS) e ainda refere-se a recursos e métodos de monitoração da progressão clínica de infecção de HIV e sua resposta à terapia anti-retroviral, particularmente terapia inibidora de transcriptase reversa de nucleosídeo empregando ensaios de suscetibilidade fenotípica ou ensaios genotípicos."RESOURCES AND METHODS FOR MONITORING ANTI-RETROVIRAL THERAPY INHIBITING NUCLEOSIDE REVERSE TRANSCRIPTASE AND GUIDE TO THERAPEUTIC DECISIONS IN TREATING HIV / AIDS". This invention relates to susceptibility and resistance tests to antiviral drugs to be employed in identifying effective drug regimens for the treatment of human immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome (AIDS) and further relates to resources and methods for monitoring the clinical progression of HIV infection and its response to antiretroviral therapy, particularly nucleoside reverse transcriptase inhibitory therapy employing phenotypic susceptibility or genotypic assays.

BR9912209-0A 1998-06-24 1999-06-24 Resources and methods for monitoring nucleoside reverse transcriptase inhibitor antiretroviral therapy and guide therapeutic decisions in the treatment of HIV / AIDS BR9912209A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10429598A 1998-06-24 1998-06-24
PCT/US1999/014486 WO1999067427A1 (en) 1998-06-24 1999-06-24 Means and methods for monitoring nucleoside reverse transcriptase inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of hiv/aids

Publications (1)

Publication Number Publication Date
BR9912209A true BR9912209A (en) 2002-11-05

Family

ID=22299700

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9912209-0A BR9912209A (en) 1998-06-24 1999-06-24 Resources and methods for monitoring nucleoside reverse transcriptase inhibitor antiretroviral therapy and guide therapeutic decisions in the treatment of HIV / AIDS

Country Status (9)

Country Link
EP (1) EP1015642A4 (en)
JP (1) JP2003503004A (en)
CN (1) CN1154747C (en)
AU (1) AU769927B2 (en)
BR (1) BR9912209A (en)
CA (1) CA2341679A1 (en)
MX (1) MXPA00012843A (en)
NZ (1) NZ508981A (en)
WO (1) WO1999067427A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7037644B1 (en) 1998-05-26 2006-05-02 Virologic, Inc. Means and methods for monitoring non-nucleoside reverse transcriptase inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS
AU783235B2 (en) 1999-05-28 2005-10-06 Virco Bvba New mutational profiles in HIV-1 reverse transcriptase correlated with phenotypic drug resistance
US7138231B2 (en) 2000-09-15 2006-11-21 Monogram Biosciences, Inc. Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS
US6869759B1 (en) 1999-06-22 2005-03-22 Virologic, Inc. Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS
US7186506B1 (en) 2000-06-12 2007-03-06 Monogram Biosciences, Inc. Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS
AU2007203337B2 (en) * 2000-04-18 2009-12-17 Virco Bvba Methods for measuring drug resistance
JP5156163B2 (en) * 2000-04-18 2013-03-06 ビルコ・ビーブイビーエイ Drug resistance measurement method
AU2631602A (en) 2000-10-20 2002-04-29 Virco Nv New mutational profiles in hiv-1 reverse transcriptase correlated with phenotypic drug resistance
US6958211B2 (en) 2001-08-08 2005-10-25 Tibotech Bvba Methods of assessing HIV integrase inhibitor therapy
US7384734B2 (en) 2002-02-15 2008-06-10 Monogram Biosciences, Inc. Compositions and methods for determining the susceptibility of a pathogenic virus to protease inhibitors
DE60327768D1 (en) 2002-07-01 2009-07-09 Tibotec Pharm Ltd MUTATIONAL PROFILES IN PHENOTYPIC MEDICAMENT RESISTANCE OF CORRELATED HIV-1 PROTEASE
AU2003256460A1 (en) 2002-07-01 2004-01-19 Virologic, Inc. Compositions and methods for determining the susceptibility of a pathogenic virus to protease inhibitors
EP1552023A4 (en) 2002-07-01 2007-04-04 Virologic Inc Compositions and methods for determining the susceptibility of a pathogenic virus to protease inhibitors
CA2490764C (en) 2002-07-01 2011-11-22 Tibotec Pharmaceuticals Ltd. New mutational profiles in hiv-1 reverse transcriptase correlated with phenotypic drug resistance
US8178291B2 (en) 2005-02-18 2012-05-15 Monogram Biosciences, Inc. Methods and compositions for determining hypersusceptibility of HIV-1 to non-nucleoside reverse transcriptase inhibitors
CA2609910A1 (en) 2005-05-27 2006-12-07 Monogram Biosciences, Inc. Methods and compositions for determining resistance of hiv-1 to protease inhibitors
WO2006133267A2 (en) 2005-06-06 2006-12-14 Monogram Biosciences, Inc. Methods and compositions for determining altered susceptibility of hiv-1 to anti-hiv drugs
US10480037B2 (en) 2011-09-23 2019-11-19 Laboratory Corporation Of America Holdings Methods and systems for predicting HIV-1 coreceptor tropism
CN103965302B (en) * 2013-01-29 2019-05-28 军事科学院军事医学研究院微生物流行病研究所 A kind of recombination super antigen SEB mutant, preparation method and application

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11502727A (en) * 1996-01-26 1999-03-09 イノジェネティックス・ナムローゼ・フェンノートシャップ Methods for detecting drug-induced mutations in the reverse transcriptase gene
JP4183749B2 (en) * 1996-01-29 2008-11-19 ビロロジック・インコーポレーテッド Compositions and methods for determining antiviral susceptibility and resistance and screening of antiviral agents

Also Published As

Publication number Publication date
CN1332804A (en) 2002-01-23
WO1999067427A1 (en) 1999-12-29
EP1015642A4 (en) 2005-03-23
MXPA00012843A (en) 2002-04-24
JP2003503004A (en) 2003-01-28
WO1999067427A9 (en) 2000-03-30
AU769927B2 (en) 2004-02-12
AU4961199A (en) 2000-01-10
EP1015642A1 (en) 2000-07-05
CA2341679A1 (en) 1999-12-29
NZ508981A (en) 2004-02-27
CN1154747C (en) 2004-06-23

Similar Documents

Publication Publication Date Title
BR9912209A (en) Resources and methods for monitoring nucleoside reverse transcriptase inhibitor antiretroviral therapy and guide therapeutic decisions in the treatment of HIV / AIDS
BR0011939A (en) Resources and methods for monitoring protease-inhibiting antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV / AIDS
BR9911600A (en) Resources and methods for monitoring non-nucleoside reverse transcriptase inhibitor antiretroviral therapy
BR0011555A (en) Mutational profiles in hiv-1 reverse transcriptase correlated with phenotypic drug resistance
BIGGAR et al. Cancer in a group at risk of acquired immunodeficiency syndrome (AIDS) through 1984
Evon et al. Fatigue in patients with chronic hepatitis B living in North America: results from the hepatitis B research network (HBRN)
Shiri et al. Lead poisoning and recurrent abdominal pain
Roca et al. Hepatitis C virus and human immunodeficiency virus coinfection in Spain
Walsh et al. Ledipasvir–sofosbuvir and sofosbuvir plus ribavirin in patients with chronic hepatitis C and bleeding disorders
ATE356994T1 (en) SCREENING METHOD WITH PIM1-KINASE OR PIM3-KINASE
Isakov et al. Sofosbuvir/velpatasvir for the treatment of HCV: excellent results from a phase-3, open-label study in Russia and Sweden
BR0111575A (en) Means and methods for monitoring antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV / AIDS
Gibson et al. Sensitive detection of HIV-1 resistance to Zidovudine and impact on treatment outcomes in low-to middle-income countries
Sharma et al. Impaired cognition predicts falls among women with and without HIV infection
WO2002022781A3 (en) Non-nucleoside reverse transcriptase inhibitor as antiretroviral therapy
DK1390531T3 (en) Quantitative diagnostic analysis of the predisposition to hypertension
MXPA03003476A (en) New mutational profiles in hiv-1 reverse transcriptase correlated with phenotypic drug resistance.
Lee et al. The use of total lymphocyte count (TLC) as an independent criterion for initiating HAART in resource-poor countries
DE60321466D1 (en) MUTATION PROFILES CORRELATED WITH PHENOTYPIC MEDICAMENT RESISTANCE IN HIV-1 REVERSE TRANSCRIPTASE
Yozviak et al. Effectiveness and tolerability of nevirapine, stavudine, and lamivudine in clinical practice
Stecher et al. Drug Resistance Spread in 6 Metropolitan Regions, Germany, 2001–2018
Smith New York City HIV superbug: fear or fear not?
Davies et al. Combined antiviral treatment in HIV infection. Is it value for money?
Fiscus et al. Baseline resistance to nucleoside reverse transcriptase inhibitors fails to predict virologic response to combination therapy in children (PACTG 338)
Cullinan South Africa takes first steps to provide antiretrovirals

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE A 8O, 9O E 10O ANUIDADES.

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 1999 DE 28/04/2009.